or Try an Advanced Search...

    Treatment Of Hemophilia Stocks List

    Symbol Grade Name % Change
    CNTA C Centessa Pharmaceuticals plc 2.52
    BIIB C Biogen Idec Inc. -0.92
    ALNY C Alnylam Pharmaceuticals, Inc. 0.21
    QURE D uniQure N.V. -6.86
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major
    Related Stock Lists: Hemophilia Acute Intermittent Porphyria Biopharmaceutical Biotechnology Clinical Development Deficiency Hemophilia A Idiopathic Pulmonary Fibrosis Lupus Spinal Muscular Atrophy Adeno Associated Virus Alipogene Tiparvovec Alnylam Pharmaceuticals Alpha 1 Antitrypsin Alpha 1 Antitrypsin Deficiency Alzheimer's Disease Amyloid Amyloidosis Antitrypsin Deficiency Applied Genetics

    Related ETFs - A few ETFs which own one or more of the above listed Treatment Of Hemophilia stocks.

    Symbol Grade Name Weight
    BIS D ProShares UltraShort Nasdaq Biotechnology 8.07
    FBT B First Trust Amex Biotech Index Fund 6.96
    BBH B Market Vectors Biotech ETF 6.64
    GERM B ETFMG Treatments Testing and Advancements ETF 6.04
    IBBQ A Invesco Nasdaq Biotechnology ETF 5.42
    View all Treatment Of Hemophilia ETFs...
    Compare ETFs
    Compare BIS to FBT Compare BIS to GERM Compare BIS to IBBQ

        Treatment Of Hemophilia Stocks Recent News

        Date Stock Title
        Jun 15 BIIB ALS therapy market seen increasing to nearly $1.3B by 2029
        Jun 14 BIIB Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
        Jun 14 BIIB The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)
        Jun 13 BIIB The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune
        Jun 12 BIIB Biogen Inc. (BIIB) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
        Jun 12 ALNY Citi opens upside catalyst watch on Alnylam ahead of ATTR-CM data
        Jun 12 BIIB Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab
        Jun 11 BIIB Eli Lilly Seesaws On FDA Win, And Pushes Alzheimer's Stocks Prothena, Eisai Lower
        Jun 11 BIIB FDA Advisers Like Lilly’s Alzheimer’s Drug. It’s Good News for Biogen.
        Jun 11 BIIB Eli Lilly (LLY) Alzheimer's Drug Donanemab Gets FDA Panel Nod
        Jun 11 BIIB Donanemab approval would fuel growth of amyloid-blocking Alzheimer’s drugs, analysts say
        Jun 11 BIIB Why Is Eli Lilly Stock Trading Higher Premarket Tuesday?
        Jun 10 BIIB FDA panel votes unanimously for Eli Lilly's Alzheimer's treatment
        Jun 10 BIIB Biogen, Eisai get January 2025 FDA action date for monthly Leqembi
        Jun 10 CNTA Centessa Pharmaceuticals appoints John Crowley as finance chief
        Jun 10 BIIB Eli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug
        Jun 10 BIIB Biogen (BIIB) & Eisai's Leqembi sBLA Gets FDA Acceptance
        Jun 10 CNTA Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer
        Related Industries: Biotechnology Drug Manufacturers - Major
        Related Stock Lists: Hemophilia Acute Intermittent Porphyria Biopharmaceutical Biotechnology Clinical Development Deficiency Hemophilia A Idiopathic Pulmonary Fibrosis Lupus Spinal Muscular Atrophy Adeno Associated Virus Alipogene Tiparvovec Alnylam Pharmaceuticals Alpha 1 Antitrypsin Alpha 1 Antitrypsin Deficiency Alzheimer's Disease Amyloid Amyloidosis Antitrypsin Deficiency Applied Genetics
        Treatment Of Hemophilia

        Treatment of hemophilia typically involves the use of replacement therapy, which involves infusions of clotting factor concentrates. These concentrates are made from donated human plasma and are designed to replace the missing clotting factor in the blood. Other treatments may include physical therapy, medications to reduce pain and swelling, and surgery to repair damaged joints.

        Browse All Tags